Literature DB >> 23887856

Current practice in neuropsychological outcome reporting after aneurysmal subarachnoid haemorrhage.

Martin N Stienen1, Rahel Weisshaupt, Javier Fandino, Christian Fung, Emanuela Keller, Gerhard Hildebrandt, Aline Studerus-Germann, Rene Müri, Klemens Gutbrod, Stefan Bläsi, Andreas U Monsch, Peter Brugger, Christian Mondadori, Martin Sailer, Philippe Bijlenga, Karl Schaller, Bawarjan Schatlo.   

Abstract

BACKGROUND: Neuropsychological deficits (NPD) are common in patients with aneurysmal subarachnoid haemorrhage (aSAH). NPD are one of the major limiting factors for patients with an otherwise acceptable prognosis for sustained quality of life. There are only a few studies reporting outcome after aSAH, which used a standardized neuropsychological test battery as a primary or secondary outcome measure. Aim of this study was to determine the current practice of reporting NPD following aSAH in clinical studies.
METHODS: A MEDLINE analysis was performed using the search term "subarachnoid haemorrhage outcome". The latest 1,000 articles were screened. We recorded study design, number of patients, and the presence of neuropsychological outcome report. Additionally, the time of testing after aSAH, the neuropsychological tests administered, as well as the percentage of patients with NPD were analyzed.
RESULTS: A total of 324 publications between 2009 and 2012 were selected for further review. Of those, 21 studies (6.5%) reported neuropsychological outcome, in 2,001 of 346,666 patients (0.6%). The assessment of NPD differed broadly using both subjective and objective cognitive evaluation, and a large variety of tests were used.
CONCLUSION: Neuropsychological outcome is underreported, and there is great variety in assessment in currently published clinical articles on aSAH. Prospective randomized trials treating aSAH may benefit from implementing more comprehensive and standardized neuropsychological outcome measures. This approach might identify otherwise unnoticed treatment effects in future interventional studies of aSAH patients.

Entities:  

Mesh:

Year:  2013        PMID: 23887856     DOI: 10.1007/s00701-013-1823-9

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  9 in total

1.  Prioritization and Timing of Outcomes and Endpoints After Aneurysmal Subarachnoid Hemorrhage in Clinical Trials and Observational Studies: Proposal of a Multidisciplinary Research Group.

Authors:  Martin N Stienen; Johanna M Visser-Meily; Tom A Schweizer; Daniel Hänggi; R Loch Macdonald; Mervyn D I Vergouwen
Journal:  Neurocrit Care       Date:  2019-06       Impact factor: 3.210

2.  Hippocampal damage and affective disorders after treatment of cerebral aneurysms.

Authors:  Maria Wostrack; Benjamin Friedrich; Katrin Hammer; Kathrin Harmening; Anne Stankewitz; Florian Ringel; Ehab Shiban; Tobias Boeckh-Behrens; Sascha Prothmann; Claus Zimmer; Bernhard Meyer; Annette Förschler; Yu-Mi Ryang
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

3.  Valproic acid attenuates intercellular adhesion molecule-1 and E-selectin through a chemokine ligand 5 dependent mechanism and subarachnoid hemorrhage induced vasospasm in a rat model.

Authors:  Chih-Zen Chang; Shu-Chuan Wu; Chih-Lung Lin; Aij-Lie Kwan
Journal:  J Inflamm (Lond)       Date:  2015-04-02       Impact factor: 4.981

4.  4'-O-β-D-glucosyl-5-O-methylvisamminol, an active ingredient of Saposhnikovia divaricata, attenuates high-mobility group box 1 and subarachnoid hemorrhage-induced vasospasm in a rat model.

Authors:  Chih-Zen Chang; Shu-Chuan Wu; Aij-Lie Kwan; Chih-Lung Lin
Journal:  Behav Brain Funct       Date:  2015-09-22       Impact factor: 3.759

5.  Screening tools for early neuropsychological impairment after aneurysmal subarachnoid hemorrhage.

Authors:  Ilari M Rautalin; Martina Sebök; Menno R Germans; Miikka Korja; Noemi Dannecker; Olivia Zindel-Geisseler; Peter Brugger; Luca Regli; Martin N Stienen
Journal:  Neurol Sci       Date:  2019-12-04       Impact factor: 3.307

Review 6.  Montreal Cognitive Assessment for Evaluating Cognitive Impairment in Subarachnoid Hemorrhage: A Systematic Review.

Authors:  Amalia Cornea; Mihaela Simu; Elena Cecilia Rosca
Journal:  J Clin Med       Date:  2022-08-10       Impact factor: 4.964

7.  Self-perceived health status following aneurysmal subarachnoid haemorrhage: a cohort study.

Authors:  Audrey C Quinn; Deepti Bhargava; Yahia Z Al-Tamimi; Matthew J Clark; Stuart A Ross; Alan Tennant
Journal:  BMJ Open       Date:  2014-04-03       Impact factor: 2.692

8.  Purpurogallin, a natural phenol, attenuates high-mobility group box 1 in subarachnoid hemorrhage induced vasospasm in a rat model.

Authors:  Chih-Zen Chang; Chih-Lung Lin; Shu-Chuan Wu; Aij-Lie Kwan
Journal:  Int J Vasc Med       Date:  2014-11-17

9.  Arctigenin, a Potent Ingredient of Arctium lappa L., Induces Endothelial Nitric Oxide Synthase and Attenuates Subarachnoid Hemorrhage-Induced Vasospasm through PI3K/Akt Pathway in a Rat Model.

Authors:  Chih-Zen Chang; Shu-Chuan Wu; Chia-Mao Chang; Chih-Lung Lin; Aij-Lie Kwan
Journal:  Biomed Res Int       Date:  2015-10-11       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.